Levofloxacin

( DrugBank: Levofloxacin / KEGG DRUG: Levofloxacin, Levofloxacin )


5 diseases
IDDisease name (Link within this page)Number of trials
46Malignant rheumatoid arthritis1
53Sjogren syndrome1
63Idiopathic thrombocytopenic purpura1
IDDisease name (Link within this page)Number of trials
84Sarcoidosis1
299Cystic fibrosis11

46. Malignant rheumatoid arthritis


Clinical trials : 4,743 / Drugs : 3,042 - (DrugBank : 389) / Drug target genes : 205 - Drug target pathways : 253 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

53. Sjogren syndrome


Clinical trials : 448 / Drugs : 436 - (DrugBank : 104) / Drug target genes : 68 - Drug target pathways : 185 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

63. Idiopathic thrombocytopenic purpura


Clinical trials : 868 / Drugs : 544 - (DrugBank : 96) / Drug target genes : 82 - Drug target pathways : 195 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

84. Sarcoidosis


Clinical trials : 196 / Drugs : 261 - (DrugBank : 78) / Drug target genes : 73 - Drug target pathways : 183 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

299. Cystic fibrosis


Clinical trials : 1,885 / Drugs : 1,782 - (DrugBank : 252) / Drug target genes : 110 - Drug target pathways : 190 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries